Marlborough, Mass. — Sunovion Pharmaceuticals, Inc., has announced that Latuda (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult patients with schizophrenia, is now available by prescription in pharmacies across the United States and Puerto Rico. LATUDA wasapproved by the U.S. Food and Drug Administration (FDA) on Oct. 28, 2010, and is available in 40 mg and 80 mg tablet strengths.
"Schizophrenia is a devastating illness not only for those who suffer from it, but also for their families as well," said Herbert Meltzer, MD, professor of psychiatry and pharmacology, Vanderbilt University School of Medicine. "The availability of LATUDA will provide physicians with an important treatment option to help manage the symptoms of this debilitating condition."
The efficacy of LATUDA was established in four, six-week placebo-controlled studies of adult patients with schizophrenia. In these studies, LATUDA demonstrated significantly greater improvement versus placebo on the primary efficacy measures [the Positive and Negative Syndrome Scale (PANSS) total score and the Brief Psychiatric Rating Scale-derived from PANSS (BPRSd)] at study endpoint.
A total of five clinical trials contributed to understanding the short-term efficacy and tolerability profile of LATUDA.
"LATUDA is a leading product for our company and we are excited to offer this new treatment option to physicians caring for individuals with schizophrenia," said Saburo Hamanaka, chairman and CEO of Sunovion Pharmaceuticals, Inc.
Sunovion has also launched Sunovion Support, a prescription assistance program to help people who are eligible receive their medication at no cost.
More information about this program, including eligibility criteria, may be found at